Deal title Principal company/nonprofit Partner company/nonprofit Value (US$M) Start date
October
Absorption Systems to perform in vitro release tests and in vitro permeability test as well as in vivo studies for topically administered generic drugs acting on skin or in the eye Absorption Systems Group LLC Food and Drug Administration $3.50 10/9/19
ABL to provide cGMP manufacturing services for NCI to support PREVENT cancer preclinical cancer prevention program Advanced Bioscience Laboratories Inc. National Cancer Institute $50.00 10/8/19
Bioinvent to manufacture HMBD-001 for Cancer Research UK Bioinvent International AB Cancer Research UK $3.13 10/23/19
Boston Children’s to evaluate Atyr Pharma's anti-neuropilin-2 antibodies for the regulation of visceral smooth muscle contractility Boston Children’s Hospital Atyr Pharma Inc. Payment unspecified 10/22/19
Broad Institute and Inscopix to identify the targets for therapeutic development for Parkinson's disease using brain mapping platform and single-cell transcriptomics Broad Institute Inc. Inscopix Payment unspecified 10/10/19
Tmunity Therapeutics and Children's Hospital of Philadelphia to develop GPC2 Chimeric antigen receptor T cell therapy cell therapy for neuroblastoma Children's Hospital of Philadelphia Tmunity Therapeutics Inc. Payment unspecified 10/1/19
CPF and Novartis to develop RAS inhibitors against cancer CRT Pioneer Fund Novartis AG Payment unspecified 10/24/19
Abbvie to develop CFF's cystic fibrosis transmembrane conductance regulator potentiator compound for cystic fibrosis Cystic Fibrosis Foundation Abbvie Inc. Payment unspecified 10/24/19
Elevatebio and Fred Hutchinson to develop T-cell receptor immunotherapies for post-hematopoietic stem cell transplant leukemic relapse Fred Hutchinson Cancer Research Center Elevatebio Payment unspecified 10/1/19
Fred Hutch to conduct phase II study of Alkermes' ALKS-4230 in combination with Keytruda against head and neck squamous cell cancer Fred Hutchinson Cancer Research Center Alkermes plc Payment unspecified 10/21/19
Fukushima Medical University to study Tella's TLPO-001 against thymic cancer Fukushima Medical University Tella Pharma Payment unspecified 10/2/19
Imbue to supply cannabinoid products to LDN Research Trust to initiate clinical trials of low dose naltrexone for autoimmune diseases and cancers Imbue LLC LDN Research Trust Payment unspecified 10/21/19
Healx and ICR to develop novel treatments for diffuse intrinsic pontine glioma using Healnet Institute of Cancer Research London Healx Ltd. Payment unspecified 10/3/19
Arecor and JDRF to jointly research, develop and commercialize a combined pramlintide and insulin for diabetes Juvenile Diabetes Research Foundation Arecor Ltd. Payment unspecified 10/22/19
LIH to evaluate the therapeutic potential of Cantabio's drugs targeting the DJ-1 protein for Parkinson's disease Luxembourg Institute of Health Cantabio Pharmaceuticals Inc. Payment unspecified 10/21/19
Recombinetics and Mayo Clinic to develop swine models for Osteogenesis Imperfecta Mayo Clinic Foundation Recombinetics Payment unspecified 10/7/19
Ziopharm Oncology and MD Anderson Cancer Center to use nonviral gene transfer to express and evaluate neoantigen-specific T-cell receptors in T cells MD Anderson Cancer Center Ziopharm Oncology Inc. $56.50 10/28/19
Lantern and NCI to identify gene signatures to predict a response of a patient’s tumor to a drug therapy National Cancer Institute Lantern Pharma Inc. Payment unspecified 10/1/19
NCI to test Rafael’s CPI-613 in cytokine independent HTLV-1 associated adult T-cell leukemia/lymphoma National Cancer Institute Rafael Pharmaceuticals Inc. Payment unspecified 10/17/19
Biological E to develop NCI's virus like particle vaccines against BKPolyomavirus, JCV associated diseases in organ/kidney transplantation, bone marrow transplantation and Progressive multifocal leukoencephalopathy National Cancer Institute Biological E Ltd. Payment unspecified 10/28/19
Hillstream and NCATS to enter a Cooperative Research and Development Agreement to develop HDAC6-PI3K gamma Dual Inhibitors for the treatment of rare cancers, including acute myeloid leukemia and acute lymphoid leukemia using Quatramer technology National Center For Advancing Translational Sciences Hillstream Biopharma Inc. Payment unspecified 10/10/19
NHS to provide access to Vertex' Orkambi, Symkevi and Kalydeco for cystic fibrosis in England National Health Service Vertex Pharmaceuticals Inc. Payment unspecified 10/23/19
Taimed to develop and commercialize NIAID's VRC07-523LS against HIV National Institute of Allergy and Infectious Diseases Taimed Biologics Inc. Payment unspecified 10/2/19
MTTI to commercialize NIBIB's patented radiotherapeutic-177-Lu-EBRGD for glioblastoma multiforme and non-small-cell lung cancer National Institute of Biomedical Imaging and Bioengineering Molecular Targeting Technologies Inc. Payment unspecified 10/28/19
NCI and Navrogen to enter into a cooperative research and development agreement to develop drugs against tumor-mediated immuno-suppression Navrogen Inc. National Cancer Institute Payment unspecified 10/1/19
4SC and Netherlands Cancer Institute to evaluate Domatinostat in combination with Nivolumab and Ipilimumab against stage III melanoma Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis 4SC AG Payment unspecified 10/16/19
Yuyang DNU and NSCI to establish joint venture to develop treatments for dry macular degeneration and rare diseases Neural Stem Cell Institute Yuyang DNU Co. Ltd. Payment unspecified 10/7/19
NTNU to conduct phase II trial for Diamyd’s intralymphatic Diamyd against latent autoimmune diabetes in adults Norwegian University of Science and Technology Diamyd Medical AB Payment unspecified 10/15/19
Okayama University to conduct preclinical studies for Oncolys Biopharma's OBP-702 Okayama University Oncolys Biopharma Inc. Payment unspecified 10/31/19
Bicycle Therapeutics and Oxford Drug Discovery Institute to develop novel therapeutics for dementia using bicyclic peptide technology Oxford Drug Discovery Institute Bicycle Therapeutics plc Payment unspecified 10/22/19
Peter MacCallum Cancer Centre to conduct preclinical studies for Invion's IVX-PDT for anal and penile cancers Peter MacCallum Cancer Centre Invion Ltd. Payment unspecified 10/31/19
Precog to conduct phase II study of Oncolytics Biotech's pelareorep for metastatic breast cancer Precog LLC Oncolytics Biotech Inc. Payment unspecified 10/22/19
Qurient and Max-Planck-Institut für Biochemie to form joint venture to develop drugs using proteasome inhibition technology against cancer Qurient Co. Ltd. Max-Planck-Institute of Biochemistry Payment unspecified 10/4/19
Macleods Pharmaceuticals to commercialize TB Alliance's pretomanid against tuberculosis TB Alliance Macleods Pharmaceuticals Ltd. Payment unspecified 10/28/19
Mologen and Foundation for AIDS Research to evaluate lefitolimod with two broadly neutralizing antibodies in HIV infected adults receiving antiretroviral therapy The Foundation for AIDS Research Mologen Ag Payment unspecified 10/8/19
University of Birmingham and Novo Nordisk to discover disease mechanisms and targets for non-alcoholic fatty liver disease The University of Birmingham Novo Nordisk A/S Payment unspecified 10/3/19
UCLA to conduct preclinical study to evaluate Advaxis’ Lm technology in mouse tumor models of glioblastoma multiforme University of California Los Angeles Advaxis Inc. Payment unspecified 10/10/19
Allied Corp to use University of Haifa's preclinical model for the development of AC-001 against the Post traumatic stress disorder University of Haifa Allied Corp. Payment unspecified 10/28/19
University of Queensland spun out Jetra Therapeutics for the development of recombinant IL-22 against liver diseases University of Queensland Jetra Therapeutics Pty Ltd. Payment unspecified 10/30/19
Immuron and NMRC to develop and evaluate an oral therapeutic against campylobacteriosis and enterotoxigenic Escherichia coli infections US Naval Medical Research Center Immuron Ltd. $3.77 10/2/19
Motif Bio and Walter Reed Army Institute to develop aerosol formulation of iclaprim against Wound healing Walter Reed Army Institute of Research Motif Bio plc Payment unspecified 10/24/19
Washington University and Bostongene to study cancer patient's data for vaccine development Washington University in St Louis Bostongene LLC Payment unspecified 10/8/19
Washington University and Kaleido to evaluate influence of microbiome metabolic therapies on microbial and host physiology and metabolism in malnutrition Washington University School of Medicine Kaleido Biosciences Inc. Payment unspecified 10/22/19
Biomica to use Weizmann Institute’s intellectual property for the development of selective treatment for antibiotic resistant bacteria Weizmann Institute of Science Biomica Ltd. Payment unspecified 10/23/19
Wisconsin Oncology Network to evaluate Context’s Apristor combination therapy in phase II trial for women with advanced breast cancer Wisconsin Oncology Network Context Therapeutics LLC Payment unspecified 10/7/19

No Comments